Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Publication date: May 08, 2019

Parkinson’s disease (PD) patients using levodopa commonly develop dyskinesia and OFF episodes that reduce quality of life.

Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri(R) (amantadine) extended release capsules on these episodes.

Evaluate diary data from pooled Gocovri phase 3, placebo-controlled trials-analyzed for 17 hours following wake-up-at baseline and week 12.

Diaries were evaluable for 162 patients. At baseline, 67% of patients woke up OFF, with prevalence decreasing to 13% at 2 hours and then remaining relatively steady at ∼12% (range, 6-17%) across half-hour intervals thereafter. Troublesome dyskinesia prevalence rose steadily from 5% to 24% over the first 2 hours, then fluctuated between 20% and 44% through the rest of the waking day. At baseline, patients experienced a mean of 3.0 daily episodes of troublesome dyskinesia (average duration 2.0 hours each), and 2.2 daily episodes of OFF (average duration 1.1 hour each). At week 12, Gocovri-treated patients showed greater reductions than placebo in troublesome dyskinesia and OFF episodes per day (treatment difference: -1.0 episodes and -0.4 episodes, respectively) and average episode duration (treatment difference: -0.6 hours and -0.3 hours, respectively). Mean duration of individual episodes of ON without troublesome dyskinesia (Good ON) increased by 5.0 hours for Gocovri, compared with 2.0 hours for placebo. Patients taking Gocovri experienced 2.2 fewer transitions between states than patients taking placebo.

Troublesome dyskinesia and OFF occurred in the morning and throughout the waking day. Gocovri-treated patients experienced fewer, shorter episodes of both troublesome dyskinesia and OFF, thereby increasing the duration of continuous Good ON episodes and reducing the frequency of transitions between motor states.

Hauser, R.A., Kremens, D.E., Elmer, L.W., Kreitzman, D.L., Walsh, R.R., Johnson, R., Howard, R., Nguyen, J.T., and Patni, R. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. 20752. 2019 J Parkinsons Dis.

Concepts Keywords
Amantadine Tardive dyskinesia
Capsules Amantadine
Dyskinesia L-DOPA
Frequency Dyskinesia
Levodopa Geriatrics
Parkinson Amines
Placebo Parkinson’s disease
RTT
Neurological disorders
Nervous system
Branches of biology
Organ systems
Delayed action preparations
Thereafter Troublesome dyskinesia
Prevalence Dyskinesia
Prevalence troublesome dyskinesia
Blind dyskinesias

Semantics

Type Source Name
disease DOID Parkinson disease
disease MESH Parkinson disease
gene UNIPROT REST
drug DRUGBANK Caffeine
pathway BSID Release
drug DRUGBANK Amantadine
drug DRUGBANK Levodopa
disease MESH Dyskinesia

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *